Medicament combinations comprising heterocyclic compounds and a novel anticholinergic

• US 20040002502A1
• Filed: 04/08/2003
• Published: 01/01/2004
• Est. Priority Date: 04/12/2002
• Status: Abandoned Application

• Current Assignee: Kyowa Hakko Kogyo Company Limited (Kirin Holdings Company Limited)
• Original Assignee: Boehringer Ingelheim Pharma GmbH & Company Kg (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Pairet, Michel, Pieper, Michael P., Meade, Christopher John Montague, Meissner, Helmut, Banholzer, Rolf, Speck, Georg, Pohl, Gerald, Morschhaeuser, Gerd, Reichl, Richard
• Application Number:
  US10/409,402
• Publication Number:
  US 20040002502A1
• Time in Patent Office: Days
• US Class Current: 514/254.11
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0075 for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
• CPC Class Codes: A61K 9/008 comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 11/08 Bronchodilators
• CPC Class Codes: C07D 451/10 acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine

Abstract

The present invention relates to novel pharmaceutical compositions based on a new anticholinergic 1 and heterocyclic compounds 2, processes for preparing them and their use in the treatment of respiratory complaints.

Claims

1. ) A pharmaceutical composition of matter comprising, as an active substance one or more, salt of formula 1

2. ) The pharmaceutical composition of matter as recited in claim 1, characterised in that the compound of formula 2 is a compound of formula 2a,

3. ) The pharmaceutical composition of matter as recited in claim 1, characterised in that the compound of formula 2 is a compound of formula 2b,

4. ) The pharmaceutical composition of matter as recited in claim 1, characterised in that the compound of formula 2 is a compound of formula 2c,

5. ) The pharmaceutical composition of matter as recited in claim 1, characterised in that the compound of formula 2 is a compound of formula 2d,

6. ) The pharmaceutical composition of matter as recited in claim 1, characterised in that the compound of formula 2 is a compound of formula 2e,

7. ) The pharmaceutical composition of matter as recited in claim 1, characterised in that the compound of formula 2 is a compound of formula 2f,

8. ) The pharmaceutical composition of matter as recited in claim 1, characterised in that the compound of formula 2 is a compound of formula 2g,

9. ) The pharmaceutical composition of matter as recited in claim 1, according to claim 1, characterised in that the compound of formula 2 is a compound of formula 2h,

10. ) The pharmaceutical composition of matter as recited in claim 1, characterised in that the active substances 1 and 2 are present either together in a single formulation in the composition or in two separate formulations in the composition.

11. ) The pharmaceutical composition of matter as recited in claim 1, characterised in that compound of formula 1 is present in the form of the chloride, bromide, methanesulphonate or para-toluenesulphonate.

12. ) The pharmaceutical composition of matter as recited in claim 1, characterised in that compound of formula 1 is present in the form of the chloride, bromide or methanesulphonate.

13. ) The pharmaceutical composition of matter as recited in claim 1, characterised in that the weight ratios of active substances 1 to 2 are in the range from about 1:

300 to about 80;

1.

14. ) The pharmaceutical composition of matter as recited in claim 1, characterised in that a single administration corresponds to a dose of the combination of active substances 1 and 2 of about 0.01 to 1000 μ

g.

15. ) The pharmaceutical composition of matter as recited in claim 1, characterised in that it is in a form suitable for inhalation.

16. ) The pharmaceutical composition of matter as recited in claim 15, characterised in that it is an inhalable powder, a propellant-containing metered-dose aerosol or a propellant-free inhalable solution or suspension.

17. ) The pharmaceutical composition of matter as recited in claim 16, characterised in that it is an inhalable powder with a maximum average particle size of up to about 250 μ

m.

18. ) The pharmaceutical composition of matter as recited in claim 16, characterised in that it is a propellant-free inhalable solution which contains water, ethanol or a mixture of water and ethanol as solvent.

19. ) The pharmaceutical composition of matter as recited in claim 18, characterised in that the pH of the solution is about 2-7.

20. ) A method for treating inflammatory or obstructive respiratory complaints in a warm blooded animal which comprises administering to said animal a therapeutically effective amount of the pharmaceutical composition of matter as recited in claim 1.